Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Research
RF Safe Research Library
Jan 1, 2023
This in vitro study assessed 50 Hz, 100 G extremely low-frequency EMF in combination with temozolomide and radiation in T98 glioblastoma cells grown as monolayers and spheroids. Radiation plus EMF increased apoptosis-related gene expression, while temozolomide plus EMF increased autophagy marker expression compared…
Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O-Methylguanine-DNA Methyltransferase, Cyclin-D1, and p53.
Research
RF Safe Research Library
Jan 1, 2021
This in vitro study evaluated 50 Hz, 70 G electromagnetic field exposure in combination with temozolomide (TMZ) in T98 and A172 glioblastoma cell lines. The authors report that EMF plus TMZ increased cell death and reduced migration potential compared with controls. They also report increased p53 gene expression and…
Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extremely low-frequency electromagnetic field (100Hz, 100G).
Research
RF Safe Research Library
Jan 1, 2017
This in vitro study tested whether an extremely low-frequency EMF (100 Hz, 100 G) could enhance temozolomide cytotoxicity in human glioma cell lines (U87 and T98G). The authors report that combined EMF and temozolomide increased apoptosis relative to either treatment alone and was accompanied by changes in…